Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

201952 citationsJournal Articlehybrid Open Access

Authors

Makoto Aihara · The University of Tokyo

Fenghe Lu · Santen (United States)

Hisashi Kawata · Santen (Japan)

Akihiro Iwata · Santen (Japan)

Kathy Liu · Santen (United States)

Noriko Odani‐Kawabata · Santen (Japan)

Naveed Shams · Santen (United States)

Abstract

Omidenepag isopropyl demonstrated stable IOP-lowering effects and was well tolerated; 0.002% was identified as the optimal dose for phase 3 investigation.

Topics & Keywords

Glaucoma and retinal disorders Ocular Surface and Contact Lens Retinal Diseases and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Glaucoma

Volume 28, Issue 5, pp. 375-385

DOI: 10.1097/ijg.0000000000001221

Field-Weighted Citation Impact: 6.75